Cardiology

GLP-1 therapies are becoming an important focus in peripheral artery disease, especially as clinicians look beyond glucose control to improve outcomes in high-risk patients. People with diabetes and peripheral artery disease often face a difficult path, marked by poor circulation, delayed wound healing, and a higher risk of amputation. While …

Why do some patients still face heart risks even after managing blood sugar and cholesterol? This lingering issue has led researchers to explore how GLP-1 therapies may influence cardiovascular inflammation as a possible missing link. While traditional treatments focus on glucose and lipid control, growing evidence suggests inflammation may continue …

When managing type 2 diabetes, most people focus on blood sugar. However, what if one medication could also improve heart health at the same time? That is exactly what researchers are discovering about how GLP-1 drugs affect blood pressure. These medications, originally designed to control glucose, are now showing consistent …

The concept of CKM staging in primary care has gained attention as clinicians look for better ways to manage the growing overlap between cardiovascular disease, kidney disease, diabetes, and metabolic disorders. However, many providers still wonder how to translate the CKM framework into daily clinical practice. Think of CKM staging …

GLP-1 receptor agonists have reshaped the management of type 2 diabetes and obesity. However, growing interest now surrounds the potential role of GLP-1 therapy in normal-weight patients with cardiometabolic risk and whether treatment decisions should rely less on BMI alone. While body mass index remains a widely used screening tool, …

GLP-1 receptor agonists have transformed type 2 diabetes and obesity management, but the cost-effectiveness of GLP-1 therapies is now at the center of payer and policy debates. With drugs like semaglutide, liraglutide, dulaglutide, and tirzepatide expanding beyond glycemic control into cardiovascular and weight management, a key question remains: do their …

Changes in resting heart rate with GLP-1 receptor agonists have become an important topic in diabetes and cardiometabolic care. As glucagon-like peptide-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide gain widespread use, clinicians often notice a modest rise in resting heart rate. Should this increase raise concern, especially in …

The potential link between GLP-1 therapies and atrial fibrillation is drawing increasing clinical interest as cardiometabolic care continues to evolve. Patients with type 2 diabetes face a significantly higher risk of atrial fibrillation, yet GLP-1 receptor agonists are rarely discussed in rhythm management conversations. Could medications such as semaglutide (Ozempic), …

A patient’s A1C can look acceptable on paper while everything else is quietly heading in the wrong direction. Cardiovascular risk is rising, kidney function is slipping, and the patient keeps missing follow-up visits because of cost, transportation, or work constraints. Most clinicians have seen this scenario play out, even when …

GLP-1–based therapies have quickly become a cornerstone of modern diabetes care. While most clinicians think of these agents for glucose lowering and weight loss, growing evidence suggests they may also support better blood pressure control. For patients living with diabetes and hypertension, that overlap raises an important question. Can GLP-1 …